The CDC, NIH & Bill Gates Own the Patents On Existing Ebola & Related Vaccines: Mandatory Vaccinations Are Near
Human ebola virus species and compositions and methods thereof CA 2741523 A1
Amazingly, the CDC owns "the" patent on Ebola and all future strains. The "SUMMARY OF THE INVENTION" section of the patent document also clearly claims that the U.S. government is claiming "ownership" over all Ebola viruses that share as little as 70% similarity with the Ebola it "invented": Why would a government organization claim to have "invented" this infectious disease and then claim a monopoly over its exploitation for commercial use? It is clear that the CDC plans to claim royalties on Ebola vaccines. This certainly increases the likelihood that the vaccines will become mandatory, thus increasing the profit potential for the patent holders.Publication number | CA2741523 A1 |
Publication type | Application |
Application number | CA 2741523 |
PCT number | PCT/US2009/062079 |
Publication date | Apr 29, 2010 |
Filing date | Oct 26, 2009 |
Priority date | Oct 24, 2008 |
Also published as | EP2350270A2, 4 More » |
Inventors | Jonathan S. Towner, Stuart T. Nichol, James A. Comer, Thomas G. Ksiazek, Pierre E. Rollin |
Applicant | Jonathan S. Towner, 5 More » |
Export Citation | BiBTeX, EndNote, RefMan |
Classifications (21), Legal Events (1) | |
External Links: CIPO, Espacenet |
- Crucell is developing an Ebola vaccine in collaboration with the Vaccine Research Center (VRC) of the NIH National Institute of Allergy and Infectious Diseases (NIAID). It has been shown to completely protect monkeys against the virus with a single dose of the vaccine.
- Under the terms of the agreement with VRC, Crucell has an option for exclusive worldwide commercialization rights to the Ebola vaccine.
- Crucell’s Ebola vaccine entered Phase I clinical trials in Q3 2006. Two groups of 16 volunteers were enrolled and vaccinated. The study showed safety and immunogenicity at the doses evaluated.
- In October 2008, Crucell secured a NIAID/NIH award to advance the development of Ebola and Marburg vaccines, with the ultimate aim of developing a multivalent filovirus vaccine.
- The award provides funding of up to $30 million, with additional options, worth a further $40 million.
Comments
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment
Comment